Sinovac Biotech Ltd (SVA) income statement
SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 7/30
$6.47+0.00 (0.00%)
Close on Nov 18, 2026Market cap $464.94MP/E –Yield 850.08%
Sinovac Biotech Ltd income statement
Ratios
Latest available, balances at Dec 31, 2025
Profitability, FY2025
- Gross margin
- 67.9%
- Operating margin
- -127.0%
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 4.59
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 31.7%
Valuation
- P/E ratio
- –
- Price to sales
- 1.20
- Price to book
- 0.10
- Dividend yield
- 850.08%
See a number that looks wrong?